SF3B1 and acute myeloid leukemia: Although clinical tests were unsuccessful in detecting changes of disease status at post-BMT compared to pre-BMT (Supplementary Table 4B), single-cell DNA-seq uncovered expansion of the oncogenic clone of cells carrying both TP53 and SF3B1 mutations from 0% before BMT to ~0.2% after BMT and then expansion to ~6% at AML relapse (Fig. 1D and Supplementary Table 4B), implying that exclusive and remarkable expansion of this oncogenic clone of cells might be the cause of AML relapse in this patient.